Loading
An indolent lymphoma can change into an aggressive one, usually by acquiring new genetic faults in the same clone. It is the commonest reason a person who has been well for years becomes unwell quickly, and it is treated as the aggressive disease rather than the original one.
Transformation is a change in the behaviour of a clone, not the arrival of a second cancer. A follicular lymphoma that has been watched for years can acquire MYC rearrangement, TP53 loss or CDKN2A deletion and start behaving as a diffuse large B-cell lymphoma. Chronic lymphocytic leukaemia can do the same, and that version has its own name, Richter transformation.
The genetics of Richter transformation were read across 86 pathologically proven cases: TP53 disruption in 47.1% and MYC abnormality in 26.2% were the dominant lesions, while the usual drivers of de novo diffuse large B-cell lymphoma were rare or absent. Whether the large-cell clone is related to the leukaemic clone matters more than any drug does: clonally unrelated cases had median survival of 62.5 months against 14.2 months for related ones, and less TP53 disruption, 23.1% against 60.0% (Rossi 2011).
What prompts the suspicion: a single node or site growing much faster than the rest, new B symptoms, a rising LDH, or a PET scan with one area far brighter than the others. What settles it is a biopsy of the brightest area, because the question is answered by tissue and nothing else answers it.
What changes: treatment moves to an aggressive-lymphoma regimen, the clonal relationship is worth establishing because it changes the expected course, and a trial is often the right answer in Richter transformation, where outcomes with standard chemoimmunotherapy are poor.
In plain words · MYC (Myc proto-oncogene protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Skin cancer, Multiple myeloma and 5 more.
Showing the target this term concerns: MYC.
Shares POD24: progression of follicular lymphoma within two years, and why it changes the plan, FLIPI, FLIPI2 and POD24 (follicular lymphoma risk), Waldenström macroglobulinaemia, Marginal zone lymphoma.
Shares POD24: progression of follicular lymphoma within two years, and why it changes the plan, FLIPI, FLIPI2 and POD24 (follicular lymphoma risk), Waldenström macroglobulinaemia, Marginal zone lymphoma.
Shares POD24: progression of follicular lymphoma within two years, and why it changes the plan, Marginal zone lymphoma, Follicular lymphoma, Non-Hodgkin lymphoma (all types).
Shares FLIPI, FLIPI2 and POD24 (follicular lymphoma risk), Waldenström macroglobulinaemia, Marginal zone lymphoma, Follicular lymphoma.
Shares Deauville score and PET-adapted therapy, Waldenström macroglobulinaemia, Marginal zone lymphoma, Follicular lymphoma.
Shares Richter transformation of chronic lymphocytic leukaemia, Clonal evolution & minimal residual disease, Marginal zone lymphoma, Follicular lymphoma.
Shares FLIPI, FLIPI2 and POD24 (follicular lymphoma risk), FDG PET, Follicular lymphoma, Non-Hodgkin lymphoma (all types).
Shares Richter transformation of chronic lymphocytic leukaemia, Cytogenetics and FISH, MYC, Follicular lymphoma.